---
title: "Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286568391.md"
description: "Preliminary data from the MIRACLE Trial reveals an impressive 40% overall complete remission rate in a challenging group of AML patients. This trial, which includes a diverse patient population, is showing promising results."
datetime: "2026-05-15T12:32:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286568391.md)
  - [en](https://longbridge.com/en/news/286568391.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286568391.md)
---

# Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Preliminary data from the MIRACLE Trial reveals an impressive 40% overall complete remission rate in a challenging group of AML patients. This trial, which includes a diverse patient population, is showing promising results.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Moleculin Nears First Unblinding in Pivotal MIRACLE Trial](https://longbridge.com/en/news/286263542.md)
- [Moleculin Biotech Q1 net loss widens as R&D costs rise](https://longbridge.com/en/news/286567662.md)
- [Moleculin highlights favorable cardiac safety data for Annamycin](https://longbridge.com/en/news/286120143.md)
- [BeOne's Venclexta challenger Beqalzi nets FDA approval](https://longbridge.com/en/news/286315985.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)